Researchers announced that Deliver Biosciences has been awarded the 2026 Fortis Grant Series, aimed at advancing new therapeutic technologies. This grant will support the development of VHH antibodies, which are smaller and more effective than traditional antibodies. These VHH antibodies can better penetrate dense tissues, such as solid tumors, making them a promising alternative for treating serious diseases like cancer and autoimmune disorders.

This is significant for anyone interested in healthy aging and longevity. If successful, these new therapies could lead to better treatment options for conditions that currently have limited solutions. For example, advancements in targeted drug delivery could enhance treatments for diseases like HIV, sickle cell disease, and neurodegenerative disorders. This means that in the near future, people might have access to more effective therapies that can improve their health and quality of life.

The research is in its early stages, with Deliver Biosciences focusing on developing targeted drug delivery technologies. The Fortis Grant Series aims to bridge the gap between innovative research and practical applications, providing organizations with the necessary resources to expedite their work. While this initiative shows promise, it’s important to note that these therapies are still in development and not yet available for public use.

For those interested in the future of healthcare, staying informed about advancements in targeted therapies and antibody technologies could be beneficial. Engaging with reputable health news sources can help you keep track of breakthroughs that may impact your health and longevity in the years to come.

Source: globenewswire.com